Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma

Takumi Kumai, Takayuki Ohkuri, Toshihiro Nagato, Yoshinari Matsuda, Kensuke Oikawa, Naoko Aoki, Shoji Kimura, Esteban Celis, Yasuaki Harabuchi, Hiroya Kobayashi

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


HER-3 expression has been reported to act as an important oncoprotein in head and neck squamous cell carcinoma. This protein is known to control tumor proliferation and acquisition of resistance by tumor cells towards EGFR inhibitors, therefore, development of a HER-3-targeted therapy is desirable. In this study, we found that HER-3 expression on tumor cells was increased after EGFR inhibition. To establish a novel therapeutic approach for HER-3-positive head and neck carcinoma, we identified a HER-3 helper epitope that could elicit effective helper T cell responses to the naturally processed HER-3-derived epitope presented in a HER-3 expressing tumors. This epitope induced potent cytolytic activity of CD4 T cells against such tumor cells. Moreover, pan HER-family tyrosine kinase inhibitor augmented the responses of HER-3-reactive CD4 T cells via upregulation of HLA-DR protein on the surface of tumor cells. Our results supports the validity of CD4 T cell-dependent HER-3-targeted therapy combined with a broad inhibitor of HER-family.

Original languageEnglish (US)
Article number16280
JournalScientific reports
StatePublished - Nov 5 2015
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this